Who are DUOSTIM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): rhFSH+rhLH, Follitropin alfa and lutropin alfa, Menopur® Inj., COS with GnRH antagonists and HP-HMG, Ovarian Stimulation with CC+rFSH.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/duostim.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DUOSTIM — Competitive Intelligence Brief

DUOSTIM (DUOSTIM) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin combination therapy. Area: Reproductive Medicine / Fertility.

phase 3 Gonadotropin combination therapy FSH receptor and LH receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

DUOSTIM (DUOSTIM) — Centre Hospitalier Intercommunal Creteil. DUOSTIM is a dual stimulation protocol combining FSH and LH for controlled ovarian hyperstimulation in assisted reproductive technology.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DUOSTIM TARGET	DUOSTIM	Centre Hospitalier Intercommunal Creteil	phase 3	Gonadotropin combination therapy	FSH receptor and LH receptor
rhFSH+rhLH	rhFSH+rhLH	Fundación Santiago Dexeus Font	marketed	Gonadotropin	FSH receptor and LH receptor
Follitropin alfa and lutropin alfa	Follitropin alfa and lutropin alfa	D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology	marketed	Gonadotropin	FSH receptor and LH receptor
Menopur® Inj.	Menopur® Inj.	LG Life Sciences	marketed	Gonadotropin	FSH receptor and LH receptor
COS with GnRH antagonists and HP-HMG	COS with GnRH antagonists and HP-HMG	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Gonadotropin protocol / Assisted reproductive technology regimen	GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins)
Ovarian Stimulation with CC+rFSH	Ovarian Stimulation with CC+rFSH	Fundación Santiago Dexeus Font	marketed	Gonadotropin combination therapy	FSH receptor (FSHR); estrogen receptor (ER) antagonism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gonadotropin combination therapy class)

Centre Hospitalier Intercommunal Creteil · 1 drug in this class
Fundación Santiago Dexeus Font · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DUOSTIM — Competitive Intelligence Brief. https://druglandscape.com/ci/duostim. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab